The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How close are we to offering treatment tailored to mutational profile?

Jul 9, 2020

During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile.

How close are we to offering treatment tailored to mutational profile?

Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including

  • midostaurin (FLT3 inhibitor) for the frontline setting
  • ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
  • enasidenib (IDH2 inhibitor) for the R/R setting
  • gilteritinib (FLT3 inhibitor) for the R/R setting

He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.